This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The hypothesis of this study is that induction of cytochrome P4503A (CYP3A) by rifampin (RIF) will be partially counteracted by the inhibitory effect of ATV on CYP3A, and the net effect of co-administered ATV and RIF, under the higher dose condition at least, will result in ATV plasma PK profiles comparable to historical controls who received ATV 400 mg every 24 hours. Primary objectives are 1) to determine whether co-administering either 300 mg or 400 mg of ATV every 12 hours with RIF 600 mg every 24 hours to HIV-seronegative volunteers maintains steady state ATV plasma drug concentrations comparable to those achieved with ATV 400 mg once daily without RIF, and 2) to assess safety and tolerability of 300 mg or 400 mg of ATV administered every 12 hours with RIF 600 mg every 24 hours in HIV-seronegative volunteers.
Showing the most recent 10 out of 515 publications
